20 August 2021 - UK chief medical officers to confirm how antibody cocktail will be rolled-out on the National Health Service (NHS) in the coming weeks.

Regeneron Pharmaceuticals today announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorisation for the casirivimab and imdevimab antibody cocktail, known as Regen-Cov in the U.S. and Ronapreve in the UK and other countries, to prevent and treat acute COVID-19 infection. 

In addition to the conditional marketing authorisation, which affects people in England, Scotland and Wales, the MHRA has also authorised emergency supply of the antibody cocktail to prevent and treat acute COVID-19 infection for people in Northern Ireland.

Read Regeneron Pharmaceuticals press release